PROTEOMIC ANALYSIS OF CARFILZOMIB (CFZ) RELATED HEART FAILURE IN MULTIPLE MYELOMA (MM) PATIENTS FROM PROSPECTIVE STUDY OF CARDIAC EVENTS DURING PROTEASOME INHIBITOR THERAPY (PROTECT) STUDY

被引：0
|
作者：
Shabnaz, S. [1 ]
Williams, R. [1 ]
Rubinstein, S. [2 ]
Fradley, M. [3 ]
Baz, R. [4 ]
Pepine, C. [1 ]
Lenihan, D. [5 ]
Cornell, R. [6 ]
Gong, Y. [1 ]
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Univ N Carolina, Chapel Hill, NC USA
[3] Univ Penn, Philadelphia, PA USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] St Francis Med Ctr, Cape Girardeau, MO USA
[6] AbbVie, Chicago, IL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-052
引用
收藏
页码：S61 / S61
页数：1
相关论文
共 50 条
  • [31] Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
    Samuel, David
    Martin, Thomas
    Wang, Michael
    Vij, Ravi
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Lonial, Sagar
    Kukreti, Vishal
    Bahlis, Nizar J.
    Alsina, Melissa
    Chanan-Khan, Asher A.
    Somlo, George
    Buadi, Francis
    Reu, Frederic J.
    Zonder, Jeffrey A.
    Song, Kevin
    Stadtmauer, Edward
    Wong, Alvin F.
    Vallone, Marcy
    Chang, Yu-Lin
    Kauffman, Michael
    Orlowski, Robert Z.
    Stewart, A. Keith
    Singhal, Seema B.
    BLOOD, 2010, 116 (21) : 433 - 433
  • [32] Incidence of atrial and ventricular arrhythmias in heart failure patients treated by cardiac resynchronization therapy: a prospective, observational study
    Boveda, S.
    Marijon, E.
    Bulava, A.
    Cebron, J. P.
    Defaye, P.
    Delarche, N.
    Lambiez, M.
    Chevalier, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2007, 6 : 174 - 174
  • [33] Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study
    Rosenbaum, Cara A.
    Kukreti, Vishal
    Zonder, Jeffrey
    Lebovic, Daniel
    Zimmerman, Todd
    Berdeja, Jesus G.
    McDonnell, Kathryn
    Waite-Marin, Jessica
    Griffith, Kent A.
    Jakubowiak, Andrzej
    BLOOD, 2014, 124 (21)
  • [34] Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
    Dimopoulos, Meletios A.
    Stewart, A. Keith
    Masszi, Tamas
    Spicka, Ivan
    Oriol, Albert
    Hajek, Roman
    Rosinol, Laura
    Siegel, David
    Mihaylov, Georgi G.
    Goranova-Marinova, Vesselina
    Rajnics, Peter
    Suvorov, Aleksandr
    Niesvizky, Ruben
    Jakubowiak, Andrzej
    San-Miguel, Jesus
    Ludwig, Heinz
    Palumbo, Antonio
    Obreja, Mihaela
    Aggarwal, Sanjay
    Moreau, Philippe
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (03) : 404 - 413
  • [35] Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study.
    Kumar, Shaji
    Bensinger, William
    Reeder, Craig B.
    Zimmerman, Todd M.
    Berenson, James R.
    Liu, Guohui
    Berg, Deborah
    Gupta, Neeraj
    Di Bacco, Alessandra
    Hui, Ai-Min
    Niesvizky, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Analysis of mortality events in ischemic heart failure patients after coronary artery bypass grafting and concomitant cardiac resynchronization therapy: results from multicenter study
    Romanov, A.
    Pokushalov, E.
    Prokhorova, D.
    Goscinska-Bis, K.
    Bis, J.
    Bochenek, A.
    EUROPEAN HEART JOURNAL, 2011, 32 : 1102 - 1102
  • [37] INSIGHT MM study of routine clinical practice in multiple myeloma: analysis of duration of therapy and treatment sequencing in UK patients
    Cook, G.
    Ashcroft, J.
    Boyd, K.
    Garg, M.
    Hall, R.
    Kishore, B.
    Moore, S.
    Smith, D.
    Crofts, N.
    Ren, K.
    Pratt, G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 126 - 127
  • [38] Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM)
    Berenson, James R.
    Hilger, James D.
    Dichmann, Robert
    Patel-Donnelly, Dipti
    Boccia, Ralph V.
    Bessudo, Alberto
    Stampleman, Laura
    Gravenor, Donald
    Eshaghian, Shahrooz
    Chamras, Hilda
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)
    Jagannath, S.
    Vij, R.
    Stewart, K.
    Somlo, G.
    Jakubowiak, A.
    Trudel, S.
    Schwartz, R.
    Siegel, D.
    Kunkel, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Nutritional status and its association with in-hospital major adverse cardiac events in patients with severe heart failure: a prospective study
    Jiang, Mei
    Sun, Mengyun
    Zhang, Xuan
    Li, Ruijian
    NUTRICION HOSPITALARIA, 2022, 39 (02) : 256 - 265
12345